In The Press

How United Theranostics Is Modernizing the Prostate Cancer Treatment Journey

Metastatic prostate cancer is on the rise among men aged 45 and older, yet treatment has long been limited to intense rounds of blanket radiation, chemotherapy, hormone therapy, or surgery to remove the prostate.

United Theranostics, a private practice offering cancer treatment using radiopharmaceuticals, is hoping to reverse that trajectory by increasing access to relatively new radioactive drugs that improve survival rates and slow tumor progression.
Read More

A Decentralized Advantage: Outpatient Theranostics is the Clinical Standard

While oncology has historically relied on a “Hospital-as-Hub” model, the specific logistical demands of radiopharmaceutical therapy (RPT) are revealing its limitations. The decentralized outpatient model is emerging as a significant industry trend, demonstrating that specialized outpatient centers can provide a higher resolution of care, particularly in areas like dosimetry and clinical trial access. This approach contrasts with traditional academic institutions by prioritizing patient convenience and optimizing specialized workflows.
Read More

Precision Cancer Care Without Borders: United Theranostics Brings Life-Saving Treatment Home

United Theranostics is redefining cancer treatment by bringing precision oncology directly to local communities through a decentralized care model. By combining advanced diagnostic imaging with targeted therapies such as Pluvicto, the company aims to make life-saving treatments more accessible. Its ambitious plan to open clinics in all 50 states within seven years could reduce patient travel burdens and strengthen local healthcare infrastructure. Beyond expanding access, United Theranostics also supports workforce development and physician training to empower community-based cancer care.
Read More